188
398 100

Lernen Sie Alnylam kennen - ein führendes Unternehmen in RNAi-Therapeutika

3:05

We Asked the Kids of Alnylam...

1:41

Alnylam（アルナイラム）企業紹介 - RNAi治療のリーディングカンパニー

2:23

Alnylam Challengers Health Equity Symposium 2024

2:01

Pathophysiology of Acute Hepatic Porphyria (AHP)

3:34

Get to Know Alnylam - The Leader in RNAi Therapeutics

2:19

RNAi, vielversprechendes Potenzial für eine neue Klasse von Medikamenten

Dieses Video wurde für ein deutsches Publikum erstellt.
Die RNA-Interferenz (RNAi) ist ein Durchbruch beim Verständnis, wie Gene in Zellen reguliert werden. Es stellt auch einen völlig neuen Ansatz in der Wirkstoffforschung und -Entwicklung dar. Der Nobelpreis für Physiologie oder Medizin 2006, der an Craig Mello und Andrew Fire verliehen wurde, würdigte die Bedeutung von RNAi als eine wichtige wissenschaftliche Entdeckung. Alnylam ist führend bei der Umsetzung von RNAi in eine völlig neue Klasse innovativer Medikamente. Erfahren Sie mehr: www.alnylam.de/unsere-wissenschaft
CORP-GAS-00002

zhlédnutí: 104

Video

Lernen Sie Alnylam kennen - ein führendes Unternehmen in RNAi-Therapeutika

3:05

Lernen Sie Alnylam kennen - ein führendes Unternehmen in RNAi-Therapeutika

zhlédnutí 236Před 2 měsíci

Dieses Video wurde für ein deutschsprachiges Publikum erstellt. Alnylam ist ein Pionier auf dem Gebiet der RNAi-Therapeutika (RNAi, RNA-Interferenz) - einer innovativen Klasse von Medikamenten, die hochspezifisch die Bildung krankheitsverursachender Proteine verhindern kann. Wir sind ein globales und schnell wachsendes biopharmazeutisches Unternehmen, das sich zum Ziel gesetzt hat, das Leben vo...

1:41

We Asked the Kids of Alnylam...

zhlédnutí 56Před 2 měsíci

During our 2023 bring your kids to work day, we asked the kids of Alnylam employees where their parent works and what do they do at Alnylam? The answers are precious! Learn more about what it's like to work at Alnylam at www.alnylam.com/careers/working-at-alnylam

Alnylam（アルナイラム）企業紹介 - RNAi治療のリーディングカンパニー

2:23

Alnylam（アルナイラム）企業紹介 - RNAi治療のリーディングカンパニー

zhlédnutí 482Před 3 měsíci

アルナイラムは、疾患の原因となる特定の遺伝子を「沈黙」させることができる革新的な医薬品である『RNAi治療薬』のパイオニアとして、たゆまぬ研究開発を続けています。世界トップクラスのバイオテクノロジー企業として、私たちは誰もが不可能だ、非現実的だという既成概念に果敢にチャレンジし、治療の選択肢が限られている日本の患者さんの生活に大きな変革をもたらします。詳細は、alnylam.jpからご覧いただけます。 CORP-JPN-00036

Alnylam Challengers Health Equity Symposium 2024

2:01

Alnylam Challengers Health Equity Symposium 2024

zhlédnutí 315Před 4 měsíci

As part of Alnylam Challengers, we aim to connect entrepreneurs, community partners and our employees to explore the challenges we collectively face and highlight inspiring solutions. We recently held one such event - our first-ever Alnylam Challengers Health Equity Symposium- at our headquarters in Cambridge, MA. This event was open to community members, industry partners and aspiring social e...

Pathophysiology of Acute Hepatic Porphyria (AHP)

3:34

Pathophysiology of Acute Hepatic Porphyria (AHP)

zhlédnutí 502Před 4 měsíci

This video was created for CEMEA audiences. The pathophysiology of porphyria comprises 8 genetic metabolic disorders of the heme biosynthesis pathway. AHP, a subset of porphyria, often presents as a sudden acute attack requiring hospitalization and is triggered by excess ALA and PBG. Watch this Mechanism of Disease video to take a deeper look at the pathogenesis, signs and symptoms, and diagnos...

Get to Know Alnylam - The Leader in RNAi Therapeutics

2:19

Get to Know Alnylam - The Leader in RNAi Therapeutics

zhlédnutí 1,7KPřed 6 měsíci

Alnylam has pioneered RNAi (RNA interference) therapeutics - an innovative class of medicines which silences the genes that cause or contribute to disease. We're a global and fast growing biopharmaceutical company driven to have a positive impact on the lives of people around the world both with our medicines and our actions outside of the lab. We invite you to learn more at alnylam.com ALN-COR...

Kim - Living with Primary Hyperoxaluria Type 1

3:39

Kim - Living with Primary Hyperoxaluria Type 1

zhlédnutí 718Před 8 měsíci

Kim is from the United States and living with primary hyperoxaluria type 1 (PH1). Primary hyperoxaluria type 1 (PH1) is a rare, inherited disease that causes the overproduction of oxalate. The excess oxalate results in the deposition of calcium oxalate crystals in the kidneys and urinary tract and can lead to the formation of painful and recurrent kidney stones. PH1 is also associated with a pr...

2:39

Who We Are: Alnylam's Core Values

zhlédnutí 1,1KPřed 8 měsíci

Our core values represent the heart of Alnylam's culture and how we work together to serve the best interests of patients and our communities. Watch this video to hear employees explain what our core values - Commitment to People, Innovation & Discovery, Sense of Urgency, Open Culture, and Passion for Excellence - mean to them and all of us. Want to learn more about our careers and our culture?...

Alnylam-Sponsored PBS Medical Stories - PH1: Bonded Hope

26:41

Alnylam-Sponsored PBS Medical Stories - PH1: Bonded Hope

zhlédnutí 2,4KPřed 11 měsíci

This film is intended for US audiences. This documentary tells the story of an amazing family with four children, three of whom are impacted by a rare metabolic disease - primary hyperoxaluria type 1, or PH1. Learn about the devastating consequences of PH1, and how for some this genetic disease means having to have a kidney and liver transplantation as a result of an underlying liver defect and...

4:49

A Family Story of AHP

zhlédnutí 880Před rokem

This video was created for US and UK audiences. Featuring the story of a family living with AHP, their journey, perspective on genetic testing and living with a hereditary condition, their information needs and how they feel about the future. AS1-USA-01486

5:27

The Importance of Genetic Testing

zhlédnutí 1KPřed rokem

This video was created for UK and Irish audiences. Siblings living with hATTR in Canada, Dan and Diana talk about their journey to diagnosis, the importance of genetic testing and their support for each other. NP-UK-00189

5:06

A Family Story of AHP

zhlédnutí 1,5KPřed rokem

This video was created for UK and Irish audiences. Featuring the story of a family living with AHP, their journey, perspective on genetic testing and living with a hereditary condition, their information needs and how they feel about the future. NP-UK-00187

One family’s journey with hereditary TTR amyloidosis: Dan and Diana

6:40

One family’s journey with hereditary TTR amyloidosis: Dan and Diana

zhlédnutí 1,6KPřed rokem

This video was created for audiences in Canada. Siblings living with hATTR in Canada, Dan and Diana talk about their journey to diagnosis, the importance of genetic testing and their support for each other. The video also includes input from their physician who talks about the benefits of diagnosing hATTR as early as possible to improve outcomes. TTR-CAN-00020

3:40

RNAi治療薬がどのように働くかを見ましょう

zhlédnutí 1,7KPřed rokem

"RNA interference (RNAi)はもともと細胞に備わっている遺伝子発現抑制（サイレンシング）の自然なプロセスです。現在の生物学や新薬開発において、最も期待され、急速に発展している最先端領域の1つです。 RNAi治療薬は、生物にもともと備わっている自然なプロセスであるRNAiを利用した新しい治療薬です。Alnylam(アルナイラム)のRNAi治療薬を構成するsmall interfering RNA(siRNA)は、RNAiを仲介する分子であり、疾患の原因となるタンパク質をコードするメッセンジャーRNA(mRNA)を特異的に分解し、疾患を引き起こすタンパク質の産生を抑制することで、疾患発症を阻止します。詳細はこちらをご覧ください www.alnylam.jp/our-science